- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05225480
Reinforcement of Placebo Response in Knee Osteoarthritis: A Randomised Trial
Saline intra-articular injections used as placebo treatments have been shown to provide pain relief in knee osteoarthritis (OA) It has further been shown that beneficial effects can be induced merely by having a conversation with a health professional.
The aim of this study is to determine whether an individual conversation based on the individual's illness perception related to knee OA affects the response to an intra-articular treatment with saline in individuals with knee OA.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite many years of research, there is still considerable uncertainty on what causes placebo effects and how these are mediated. Saline is a pharmacologically inert agent frequently used as placebo comparator in clinical trials of intra-articular (IA) treatments for knee osteoarthritis (OA) and patients often experience a significant pain improvement from this treatment even when it is administered as an open label placebo treatment.
It has further been shown that beneficial effects can be induced merely by having a conversation with a health professional and several studies have found the alliance between therapist and patient to have a positive effect on treatment outcome in physical rehabilitation indicating that positive attention by itself leads to beneficial treatment outcomes. Still it is unclear wether the effect of an open label placebo treatment can be influenced by a conversation and if the extent of this infleuence depends on the focus of the conversation.
The aim of this study is to determine whether a conversation about the individual's illness perception related to knee OA affects the response to a placebo treatment (saline injection) in individuals with knee OA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Danmark
-
Frederiksberg, Danmark, Denmark, 2000
- the Parker Institute, Bispebjerg-Frederiksberg Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥50 years
- A clinical diagnosis of tibiofemoral OA in the target knee according to the American College of Rheumatology
- Average knee pain in the last week during weight bearing activities of at least 4 on a 0 to 10 points scale (0=no pain; 10=worst possible pain).
Exclusion Criteria:
- Not able to speak or understand Danish
- Scheduled surgery during study participation
- History of target knee surgery within 12 months
- History of arthroplasty in the target knee
- Injection therapy in either knee within 3 months
- Current use of oral glucocorticoids
- Current use of synthetic or non-synthetic opioids
- Contraindications to intra-articular injections, such as wounds or skin rash over injection site.
- Planning to start or discontinue other treatment for knee OA in the study participation period
- Inflammatory arthritis, such as rheumatoid arthritis or psoriatic arthritis.
- Regional pain syndromes
- Generalised pain syndromes such as fibromyalgia
- Lumbar or cervical nerve root compression syndromes
- Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as large knee joint effusion, uncontrolled diabetes, psychiatric and/or neurological disorders, or opiate dependency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: intervention arm
The illness perception conversation will be delivered in one session during around 15 minutes. The conversation will be based on responses to the eight item Brief illness perception questionnaire and a rating of the most relevant item made by the patient on the same day. The aim of the conversation will be to get an overview of the patient's illness perceptions concerning their knee OA and what is deemed the most maladaptive perceptions by the participant. Participants will be invited to elaborate on their thoughts concerning these perceptions.Although any maladaptive perceptions will be corrected if natural during the conversation, the conversation will not lead to any active attempts of changing illness perceptions. Rather, the conversation focusses on giving patients time and opportunity to express knee pain related perceptions and worries concerning their knee pain. |
A conversation based on the indvidual's knee pain related illness perceptions
|
|
Active Comparator: control arm
The control conversation will be delivered in one session during around 15 minutes. In order to create two similar conversational settings where the only difference is the actual content of the conversations. The conversation will be based on responses to an eight item questionnaire concerning motivation for research participation and - similar to the illnes perception conversation - a rating of the most relevant item made by the patient. The aim of the conversation will be to get an overview of the patient's motivation for research participation and let them elaborate on their thoughts concerning their motivation. |
A conversation based on the indvidual's motivation for participating in research
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAS knee pain
Time Frame: Week two, change from baseline
|
Knee pain defined as "the average level of pain in your knee today" will be assessed with a 100 mm visual analogue scale (VAS) with anchors 0 = "no pain" and 100 = "Worst imaginable pain".
|
Week two, change from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of knee pain variability (VAS) prior to the intervention
Time Frame: Week 0, Change from week -1
|
The key secondary objective is to assess if pain variability in the week before treatment is a determinant of the effect of the subsequent treatment.
|
Week 0, Change from week -1
|
|
Brief Illness perception questionnaire
Time Frame: Week two, change from baseline
|
The Brief illness perception questionnaire (BIPQ) is a generic questionnaire developed to measure illness perception in a variety of illnesses.
The questionnaire is patient-reported and assesses perceptions on the following five dimensions: Identity, Cause, Timeline, Consequences and Cure-Control.
It contains eight numerical rating scales questions (0-10) and a memo field based on the patients' own beliefs about their condition.
In some circumstances it may be possible to compute an overall score which represents the degree to which the illness is perceived as threatening or benign.
To compute the score, reverse score items 3, 4, and 7 and add these to items 1, 2, 5, 6, and 8.
A higher score reflects a more threatening view of the illness.
|
Week two, change from baseline
|
|
Knee injury and Osteoarthritis Outcome Score
Time Frame: Week two, change from baseline
|
The Knee injury and Osteoarthritis Outcome Score (KOOS) is used to assess patient-reported knee-related symptoms.
The KOOS is a patient-reported outcome measurement instrument developed to assess the patient's opinion about their knee and associated problems.KOOS comprises of 42 items in 5 separately scored subdomains: KOOS Pain (9 items), KOOS Symptoms (7 items), Function in daily living (KOOS Function; 17 items), Function in Sport and Recreation (5 items), and Knee-related Quality of Life (4 items).
The previous week is the time period considered when answering the questions, and the questions relate to one knee (the target knee in this trial).
|
Week two, change from baseline
|
|
The 30 seconds sit to stand test
Time Frame: Week two, end of trial, change from baseline
|
The 30 seconds chair stand test (30sCST) is a physical performance test that quantifies how many sit-to-stand movements an individual can perform within 30 seconds.
The 30sCST is a measure of balance 500 during functional activities and lower extremity function and strength.
It is recommended as a 501 performance-based test to assess physical function in people diagnosed with hip or knee OA.
From the sitting position in the middle of seat with feet shoulder width apart, flat on the floor, arms crossed at chest, the participant is asked to stand completely up, then sit completely back down, repeatedly for 30 seconds.
The total number of complete chair stands (up and down represents one stand) is counted.
There is given only one trial.
If a full stand is completed at 30 seconds, then this is counted in the total.
The same chair is used at all assessments.
|
Week two, end of trial, change from baseline
|
|
4x10 meter fast walk test
Time Frame: Week two, change from baseline
|
The 4x10 meter fast walk test (40mFWT) is a physical performance test that quantifies short distance walking performance. The 40mFWT is a measure of walking speed over short distances and changing direction during walking. It is recommended as a performance-based test to assess physical function in people diagnosed with hip or knee OA (26). The participant is asked to walk as quickly but as safely as possible to a mark 10 m away, return, and repeat for a total distance of 40 m. Regular walking aid is allowed and recorded. Time of one trial, with turn time excluded, is recorded and expressed as speed m/s by dividing distance (40 m) by time (s). |
Week two, change from baseline
|
|
Stair climbing test
Time Frame: Week two, change from baseline
|
A stair climbing test (SCT) is a physical performance test that quantifies how fast an individual can ascend and descend a flight of stairs in a usual manner. The SCT is a measure of balance during functional activities and lower extremity function and strength. It is recommended as a performance-based test to assess physical function in people diagnosed with hip or knee OA. The participant is asked to ascend and descend a flight of stairs in a usual manner, and at a safe and comfortable pace. Use of any walking aid and handrail is permitted and recorded. Total time to ascend and descend steps for one trial is recorded in seconds. The same flight of stairs is used at all assessments. |
Week two, change from baseline
|
|
Expectations for Treatment Scale (ETS)
Time Frame: Week 0, change from week -1
|
The expectation for treatment scale (ETS) is a 5-item questionnaire concerning the patients' expectations of a given treatment. (E.g: 1) "I expect the treatment will help me to cope with my complaints", 2) "I expect the treatment will make my complaints disappear", 3) I expect the treatment will improve my energy", 4) "I expect the treatment will improve my physical performance" and 5) "I expect that after the treatment, my complaints will be considerably better". Each question has four response options on a likert scale: "partially disagree", "partially agree","agree", "definitely agree". We will replace the word "treatment" with "saline injection" and "complaint" with "knee pain". The questionnaire has been translated into Danish for this study. |
Week 0, change from week -1
|
|
Synovial hypertrophy score
Time Frame: Week two, change from baseline
|
Via ultrasound, the amount of synovial hypertrophy will be measured in mm in position using specific landmarks.
The following positions will be examined: 1) The medial joint space and recess (medial longitudinal scan) 2) The lateral joint space and recess (lateral longitudinal scan)
|
Week two, change from baseline
|
|
Doppler activity score
Time Frame: Week two, change from baseline
|
Via ultrasound, the Doppler activity will be measured on a semi-quantitative score from 0-3.
|
Week two, change from baseline
|
|
Self-reported paracetamol and ibuprofen use for knee pain
Time Frame: Week two, change from baseline
|
Participants will register their daily use of paracetamol and ibuprofen for knee pain
|
Week two, change from baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee joint effusion
Time Frame: Week two, change from baseline
|
As a safety outcome, the presence of knee joint effusion will be recorded for each knee as a dichotomous score (present/absent) using ultrasound.
|
Week two, change from baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marius Henriksen, Professor, the Parker Institute, Bisbebjerg and Frederiksberg Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APPI2-OA-2022-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
Istanbul University - CerrahpasaCompletedKnee Osteoarthritis | Knee Osteoarthritis (Knee OA)Turkey (Türkiye)
-
Edin MešanovićCompletedOsteoarthritis | Osteoarthritis of the Knee | Osteoarthritis of Knee | Osteoarthritis of the Knees | Osteoarthritis (OA) of the Knee | Osteoarthritis Knee | Osteoarthritis in the Knee | Osteoarthritis of Knee JointBosnia and Herzegovina
-
Golden Jubilee National HospitalJohnson & Johnson; DePuy OrthopaedicsNot yet recruitingOsteoarthritis | Knee Osteoarthritis | Osteoarthritis (OA) | Osteo Arthritis | Osteoarthritis in the Knee | Osteoarthritis (Knee) | Osteo Arthritis of the KneeUnited Kingdom
-
Dr. David WassersteinSunnybrook Research InstituteRecruitingKnee Osteoarthritis (Knee OA) | Knee Osteoarthritis (OA)Canada
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
Lucas R. Cusumano, MDNot yet recruitingKnee Osteoarthritis | Knee Discomfort | Knee Pain Chronic | Knee Swelling PainUnited States
-
Emory UniversityVertex Pharmaceuticals IncorporatedNot yet recruitingKnee Osteoarthritis | Knee ArthritisUnited States
-
VA Office of Research and DevelopmentNot yet recruitingKnee Osteoarthritis (Knee OA)United States
-
The Hong Kong Polytechnic UniversityChinese University of Hong Kong; Zhujiang HospitalNot yet recruitingKnee Osteoarthritis (Knee OA)
-
University of MiamiNot yet recruiting
Clinical Trials on Illness perception conversation
-
Hvidovre University HospitalUniversity of Southern DenmarkCompleted
-
Dartmouth-Hitchcock Medical CenterAmerican Cancer Society, Inc.CompletedCommunicationUnited States
-
Stanford UniversityTerminatedHepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Neuroendocrine Tumors | Cholangiocarcinoma | Gastrointestinal Cancer | GIST, MalignantUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingMalignant Solid Neoplasm | Endocrine Gland Neoplasms | Breast Carcinoma | Malignant Female Reproductive System Neoplasm | Malignant Thoracic Neoplasm | Malignant Head and Neck Neoplasm | Malignant Digestive System Neoplasm | Central Nervous System Neoplasm | Soft Tissue Neoplasm | Skin Neoplasm | Malignant... and other conditionsUnited States
-
University of CincinnatiOhio Third Frontier; Wright Center of Innovation in Biomedical ImagingActive, not recruitingHealthcare Facility Environment - ImagingUnited States
-
UMC UtrechtDimence GroepRecruitingAutism Spectrum Disorder (ASD) | NeurotypicalNetherlands
-
VA Office of Research and DevelopmentCompleted
-
Nottingham University Hospitals NHS TrustCompletedPhysical Activity | Moving Medicine | Acute Medical UnitUnited Kingdom
-
University of AarhusDanish Cancer Society; TrygFonden, DenmarkUnknownHeart Failure | Neoplasms | Pulmonary DiseaseDenmark
-
Harvard School of Public Health (HSPH)Active, not recruitingHealth Knowledge, Attitudes, PracticeUnited States